Pubblicazioni scientifiche sui diagnostici non invasivi BioPredictive
Studi sottoposti a revisione paritaria che convalidano i diagnostici ematici BioPredictive per le malattie del fegato — dalle coorti di sviluppo pionieristiche alle meta-analisi a lungo termine.
47/435
Risultati per
“FIB4”
-
Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
…one on ELF, four on FibroScan, four on FIB4, one on FIB4…
-
Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Meta Analysis
…APRI [0.07 (0.02-0.13)] and FIB4 vs. APRI [0…
-
Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt.
…An algorithm using the Fib4 for identifying patients with F2 stage or…
-
Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.
…BARD) and complex (Hepascore, Fibrotest, FIB4) fibrosis models were calculated in 242…
-
Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.
…For FIB4, this decrease in specificity was only related to the higher…
-
Comparison of non-invasive fibrosis markers and classical liver biopsy in chronic hepatitis C.
…The platelet count, AST/ALT ratio (AAR), cirrhosis discriminate score (CDS), FIB4…
-
Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.
…The FIB4/VCTE/FibroMeter and FIB4/VCTE/Fibrotest algorithms performed similarly, providing…
-
Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C.
…0.751-0.868)] with a significant increase for FIB4: 0.879…
-
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Key publication
…0.852; P = 0.0001), FIB4 (0.845; 0.829-0.861…
-
Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Key publication
…of nonpatented biomarkers (APRI, Forns, FIB4; P < 0.01). In multivariate analysis…
-
Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis. Key publication
### Background No prospective diagnostic studies have directly compared widespread non-invasive liver…
-
Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. Key publication
### Background Although the FibroTest has been validated as a biomarker to determine…
-
Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. Key publication
…001) than those of ActiTest, FIB4, BARD, and nonalcoholic fatty liver disease…
-
Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection Key publication
These are the first guidelines dealing with hepatitis C treatment produced by…
-
Liver fibrosis markers in alcoholic liver disease. Review
…Hepascore, Forns and APRI indexes, FIB4, an algorithm combining Prothrombin index (PI…
-
Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease.
-
External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B. Key publication
### Background And Aims The liver cancer risk test (LCR1-LCR2) is a…
-
Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV. Review
…indirect markers) such as APRI, FIB4, FibroTest, FibroSpect II, HepaScore, or imaging…
-
Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.
-
Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.
As of 2016, there is no evidence-based pathway to stratify the…
-
Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.
…to platelet ratio index (APRI), FIB4, FibroTest, Hepascore, FibroMeter(V2G)). Prognostic accuracy…
-
FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest.
### Unlabelled To optimize the management of patients with chronic hepatitis C virus…
-
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes. Key publication
### Background One of the unmet needs in patients with type 2 diabetes…
-
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. Key publication
### Background & Aims The Liver Cancer Risk test algorithm (LCR1-LCR2) is a…
-
Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C.
-
Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study.
### Background & Aims Blood tests and transient elastography (Fibroscan™) have been developed as…
-
Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus.
### Background Liver stiffness and non-invasive tests predict overall survival in chronic…
-
Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. Review
Alcoholic liver disease (ALD) consists of a broad spectrum of disorders, ranging…
-
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication Review
This review summarizes the methodological aspects of the interpretation of non-invasive…
-
Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference. Key publication
-
Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies. Meta Analysis
### Background Liver biopsy and virological end points are standard references for assessing…
-
Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso.
Liver fibrosis (LF) must be assessed before talking treatment decisions in hepatitis…
-
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
### Background & Aims Patients with chronic hepatitis C virus infection and advanced fibrosis…
-
Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
### Background In the UNITY-3 study, 96% sustained virologic response (SVR12) rate…
-
Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. Review
### Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of…
-
Impact of steatosis and inflammation definitions on the performance of NASH tests.
### Background And Aim One of the unmet needs in subjects with metabolic…
-
Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.
### Background & Aims Real-time shear wave elastography (SWE) is a new two…
-
Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients.
### Background/Aims The aim of this study was to compare the performance…
-
Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).
### Background & Aims The first aim was to extend the validation of FibroTest…
-
[Prognosis assessment of alcoholic liver disease: how and why?]. Review
Alcoholic liver disease (ALD) causes more than 5000 deaths per year in…
-
Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.
### Introduction A prognostic model to predict liver severity in people with metabolic…
-
Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).
### Background & Aims FibroTest™ (FT) and Transient Elastography (TE) have been validated as…
-
Assessment of liver fibrosis: noninvasive means.
Liver biopsy, owing to its limitations and risks, is an imperfect gold…
-
Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Key publication
**Background/Objectives:** Bariatric surgery (BS), drugs approved for type-2-diabetes (T2D…
-
Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Review
Chronic hepatitis B virus (HBV) infection is a major cause of liver…
-
EASL clinical practical guidelines: management of alcoholic liver disease.
-
Prise en charge des personnes infectées par les virus de l’hépatite B ou de l’hépatite C — Rapport de recommandations 2014 Key publication
Mostra l'elenco completo dei risultati. La pagina è renderizzata sul server e non è paginata.